Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 4 1

Status

Completed 6

Sponsor Class

INDUSTRY 6OTHER 3

Study Type

Interventional 6

Sponsor

Cancer Type

Dermatologic 6

Conditions

Keratosis, Actinic 4Carcinoma, Basal Cell 3Warts 1Carcinoma, Squamous Cell 1Bowen's Disease 1

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 329Cisplatin 276Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 210Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Has results × methyl 5-aminolevulinate × Clear all
NCT00472459 2025-04-18

Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer

Galderma R&D

Phase 3 Completed
82 enrolled 20 charts
Dermatologic

Bowen's Disease, Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Warts, Keratosis, Actinic

NCT00472043 2024-08-06

PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma

Galderma R&D

Phase 3 Completed
66 enrolled 15 charts
Dermatologic

Carcinoma, Basal Cell

NCT02144077 2022-11-03

Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy

Biofrontera Bioscience GmbH

Phase 3 Completed
281 enrolled 16 charts
Dermatologic

Carcinoma, Basal Cell

NCT01475071 2021-02-18

CoMet

Galderma R&D

Phase 3 Completed
100 enrolled 8 charts
Dermatologic

Keratosis, Actinic

NCT03511326 2021-02-18

SESAME 2

Galderma R&D

Phase 4 Completed
50 enrolled 9 charts
Dermatologic

Keratosis, Actinic

NCT02799069 2017-04-28

Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy

Biofrontera Bioscience GmbH

Phase 3 Completed
571 enrolled 46 charts
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡